Stock exchanges & markets

Overview Watchlists

Roche licenses Rona Therapeutics' ALK7-targeting RNAi obesity drug candidate in deal worth up to USD 1.16 billion

13. Oct 2026

(AWP Alliance News) - Roche Holding AG entered an exclusive worldwide license agreement with Rona Therapeutics for an investigational RNAi therapy targeting ALK7 for obesity and metabolic diseases. Rona will receive upfront and near-term milestone payments of up to USD 100 million.

The deal includes up to USD 1.06 billion in potential development, regulatory, and commercial milestones. Rona is also eligible for tiered royalties on global net sales.

https://www.prnewswire.co.uk/news-releases/rona-therapeutics-enters-int…

Disclaimer: This news brief was created using generative artificial intelligence. Roche Holding AG published the original content used to generate this news brief via PR Newswire on October 13, 2026, and is solely responsible for the information contained therein.

Learn more about our offers

  • Keep a close eye on your favourite shares

    Watchlist

    Don’t miss out on share price trends. Track your favourite shares (CH, EU & US) in real time with customised watchlists.

    Sign up now

  • Compare ETFs systematically

    ETF Compass

    Find the products that suit your investment goals.

    Try the ETF Compass

  • How to find the best shares

    theScreener

    Search through around 6,500 securities using criteria such as opportunities and risks or expected dividend yield.

    Test now